Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3 MEASURE 3 Study

OBJECTIVE: Secukinumab 150 mg has demonstrated significant improvement in signs and symptoms of ankylosing spondylitis (AS), with response rates sustained for up to 5 years. Here, we report end‐of‐study 3‐year efficacy and safety results of secukinumab 150 and 300 mg from the MEASURE 3 study. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Pavelka, Karel, Kivitz, Alan J., Dokoupilova, Eva, Blanco, Ricardo, Maradiaga, Marco, Tahir, Hasan, Wang, Yi, Porter, Brian O., Stefanska, Anna, Richards, Hanno B., Rohrer, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011421/
https://www.ncbi.nlm.nih.gov/pubmed/31957970
http://dx.doi.org/10.1002/acr2.11102

Ejemplares similares

Ejemplares similares